- Home
- ROOT vs APGE Comparison
ROOT vs APGE Comparison
Compare ROOT & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROOT
- APGE
- Stock Information
- Founded
- ROOT 2015
- APGE 2022
- Country
- ROOT United States
- APGE United States
- Employees
- ROOT N/A
- APGE N/A
- Industry
- ROOT Property-Casualty Insurers
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ROOT Finance
- APGE Health Care
- Exchange
- ROOT Nasdaq
- APGE Nasdaq
- Market Cap
- ROOT 2.3B
- APGE 2.0B
- IPO Year
- ROOT 2020
- APGE 2023
- Fundamental
- Price
- ROOT $95.81
- APGE $38.08
- Analyst Decision
- ROOT Buy
- APGE Strong Buy
- Analyst Count
- ROOT 6
- APGE 5
- Target Price
- ROOT $130.60
- APGE $95.40
- AVG Volume (30 Days)
- ROOT 438.0K
- APGE 478.9K
- Earning Date
- ROOT 10-29-2025
- APGE 11-11-2025
- Dividend Yield
- ROOT N/A
- APGE N/A
- EPS Growth
- ROOT N/A
- APGE N/A
- EPS
- ROOT 4.73
- APGE N/A
- Revenue
- ROOT $1,364,700,000.00
- APGE N/A
- Revenue This Year
- ROOT $27.41
- APGE N/A
- Revenue Next Year
- ROOT $9.74
- APGE N/A
- P/E Ratio
- ROOT $20.90
- APGE N/A
- Revenue Growth
- ROOT 59.76
- APGE N/A
- 52 Week Low
- ROOT $36.87
- APGE $26.20
- 52 Week High
- ROOT $181.14
- APGE $63.50
- Technical
- Relative Strength Index (RSI)
- ROOT 47.82
- APGE 53.11
- Support Level
- ROOT $94.78
- APGE $36.01
- Resistance Level
- ROOT $102.47
- APGE $37.97
- Average True Range (ATR)
- ROOT 4.57
- APGE 1.60
- MACD
- ROOT 1.65
- APGE 0.05
- Stochastic Oscillator
- ROOT 57.16
- APGE 75.95
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.